St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network (NCCN) Clinical
RadioMedix & Curium Announce DetectnetTM (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
Share Article
RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs). ST. LOUIS, Mo. (PRWEB) May 05, 2021 RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs). Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors in adults.
By JULIA MARI ORNEDO, GMA News
Published April 29, 2021 1:48pm The local clinical trial for the use of antiparasitic drug ivermectin on COVID-19 patients is seen to start at the end of May or in early June, an official from the Department of Science and Technology (DOST) said Thursday. Executive director Jaime Montoya of the DOST-Philippine Council for Health Research and Development said the trial will run for about six months, with Metro Manila being eyed as the venue for ease of patient recruitment. Around 1,200 patients are expected to participate, Montoya said, adding the trial will target mild and moderate COVID-19 cases who are still in quarantine facilities.
E-Mail
Organizations producing Clinical Practice Guidelines (statements designed to guide and optimize patient care for specific clinical circumstances) often have conflict-of-interest policies that fail to meet the Institute of Medicine s standards, and/or frequently violate their own stated conflict-of-interest policies potentially undermining public trust in Clinical Practice Guidelines.
###
Share this article
Share this article
Galderma is partnering with popular Canadian influencers to launch #RosaceaChallenge, challenging sufferers to face up to rosacea and carry on doing the activities they love
Thanks to advances in dermatology practice, the campaign urges rosacea sufferers to visit a family physician or dermatologist to discuss a personalized treatment plan to help them aim for clear skin
TORONTO, April 8, 2021 /CNW/ - This Rosacea Awareness Month, Galderma, the world s largest dermatology company, is collaborating with Canadian actress, Christine Solomon, and a team of influencers to launch a skin positivity movement. The #RosaceaChallenge encourages Canadians frustrated with this chronic skin condition to take action by consulting with a dermatologist or their family physician, as a first step in achieving clearer skin.